ArticleTherapeutic advances in gastroenterology2019
What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale.
Article in Therapeutic advances in gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Crohn's Colitis Care, a Disease-Specific Electronic Medical Record, Enhances Data Capture in Pediatric Inflammatory Bowel Disease Care.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems.Clinical and experimental medicine · 2025Review
- Inflammatory Bowel Disease and Joint Surgery: A 20-Year Cohort Study of Arthroplasty and Arthritis Risks.Cureus · 2025Article
- Achieving Health Equity: Advancing Colorectal Surgery among Racial and Ethnic Minorities in America.Clinics in colon and rectal surgery · 2025Review
- Coalition of explainable artificial intelligence and quantum computing in precision medicine.Computational and structural biotechnology journal · 2025Review
- Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.Advances in therapy · 2024Article
- Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal.GE Portuguese journal of gastroenterology · 2023Article
- Landscape of inflammatory bowel disease in Singapore.Intestinal research · 2022Review
- Increasing Prevalence and Direct Health Care Cost of Inflammatory Bowel Disease Among Adults: A Population-Based Study From a Western Canadian Province.Journal of the Canadian Association of Gastroenterology · 2021Article
- The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study.BMC gastroenterology · 2021Article
- Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence.Clinical and translational gastroenterology · 2020Article
- Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study.Therapeutic advances in gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is increasingly prevalent within western societies. Its complex and chronic facets in addition to its increasing prevalence place a great economic burden on our healthcare systems. Our aim was to estimate the national prevalence of IBD through predictive models. We used prevalence data which spans the years 2003-2007 to estimate prevalence until 2030 by means of four forecasting methods. Prevalence rates are estimated to be 4-6-times higher in 2030 when compared with 2003 with an average annual percent change of 5%. IBD is poised to have a substantial impact on healthcare systems in the near future, given its rapidly increasing prevalence. Forecasting methods will allow for a proactive stance on the development of health policies that will be needed to provide high quality and cost-effective care to these patients, while ensuring the economic viability of healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.